Abstract
Background: Hydroxytyrosol is one of the phenolic compounds of olive oil and can induce anticancer effects on colorectal cancer cells.
Objective: The aim of the present study was to evaluate the free hydroxytyrosol and nano-capsulated hydroxytyrosol effects on the cell cycle arrest in HT-29 colorectal cancer cell line.
Methods: The nano-capsulated hydroxytyrosol was synthesized in poly lactide-co-glycolide-co-polyacrylic acid (PLGA-PAA) copolymer. MTT assay was performed to evaluate the anti-proliferative and anti-tumor effects of the free hydroxytyrosol and nano-capsulated hydroxytyrosol. Finally, the relative expression of CDKN1A, CDKN1B, and CCND1 genes was evaluated in control and treated colorectal cancer cells by using Real-Time PCR.
Results: The obtained results from the MTT assay showed that the cytotoxic effects of the nano-capsulated hydroxytyrosol on the colorectal cancer cell line (IC50= 6PPM) were significantly more than free hydroxytyrosol (IC50= 12PPM) after 72h. Also, nano-capsulated hydroxytyrosol showed more significant effects on the upregulation of CDKN1A and CDKN1B genes and down-regulation of the CCND1 gene in colorectal cancer cells.
Conclusion: In conclusion, the present study showed that hydroxytyrosol led to the death of colorectal cancer cells through cell cycle arrest. Also, the PLGA-PAA copolymer dramatically caused to increase the cytotoxic effects of the hydroxytyrosol on the colorectal cancer cells.
Keywords: Colorectal cancer, PLGA-PAA copolymer, hydroxytyrosol, HT-29, CCND1, CDKN1A, CDKN1B.
[http://dx.doi.org/10.1186/s12943-015-0296-2] [PMID: 25645394]
[http://dx.doi.org/10.1016/S0140-6736(13)61649-9] [PMID: 24225001]
[http://dx.doi.org/10.1002/jbt.22486] [PMID: 32128952]
[http://dx.doi.org/10.1007/s12282-020-01055-6] [PMID: 32026267]
[http://dx.doi.org/10.3390/nu8080513] [PMID: 27548217]
[http://dx.doi.org/10.1038/sj.ejcn.1601497] [PMID: 12548316]
[http://dx.doi.org/10.1001/jama.295.6.655] [PMID: 16467234]
[PMID: 25988120]
[http://dx.doi.org/10.3390/foods9030292] [PMID: 32150867]
[http://dx.doi.org/10.1080/09674845.2019.1567903] [PMID: 30633636]
[http://dx.doi.org/10.2174/1874285801913010081]
[http://dx.doi.org/10.1016/j.jddst.2019.03.003]
[http://dx.doi.org/10.1007/s40618-016-0537-2] [PMID: 27592355]
[http://dx.doi.org/10.1080/01635581.2014.951727] [PMID: 25207387]
[http://dx.doi.org/10.1093/jn/138.1.42] [PMID: 18156402]
[http://dx.doi.org/10.1016/j.canlet.2014.01.028] [PMID: 24486741]
[http://dx.doi.org/10.1002/mnfr.200800269] [PMID: 19685549]
[http://dx.doi.org/10.1080/01635581.2017.1339818] [PMID: 28718667]
[http://dx.doi.org/10.1016/j.fct.2010.10.014] [PMID: 20955751]
[http://dx.doi.org/10.18632/oncotarget.20544] [PMID: 29137335]